Polymorphonuclear neutrophils and instability of the atherosclerotic plaque: a causative role? | springermedizin.de

Springer Medizin

nach oben

Inflammation Research

Erschienen in:

01.06.2013 | Review

Polymorphonuclear neutrophils and instability of the atherosclerotic plaque: a causative role?

verfasst von: Roberta Della Bona, Maria Teresa Cardillo, Milena Leo, Gina Biasillo, Massimo Gustapane, Francesco Trotta, Luigi M. Biasucci

Erschienen in: Inflammation Research | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this review is to examine the role of polymorphonuclear neutrophils (PMNs) in the evolution of atherosclerosis.

Introduction

While the role of PMNs in the evolution of atherosclerosic process has failed until recently to attract much attention, a body of research carried out over the last decade has disclosed the unexpectedly complex behavior of these cells, unraveling an unexpected key role for PMNs in the onset and progression of atheroma.

Methods

A PubMed database search was performed for studies providing evidences on the role of PMNs in the development and progression of atherosclerotic lesion.

Results and Conclusions

Activated PMNs were shown to produce and release reactive oxygen species, inflammatory leukotrienes and proteolytic lysosomal enzymes, directly inducing vascular damage. Activated PMNs also secrete myeloperoxidase, involved in lipoprotein oxidation. PMNs have a finite lifespan and typically die through apoptosis, which thus represents a counter-regulatory mechanism limiting the toxic potential of these short-lived, terminally differentiated cells. Dysregulation of this process probably contributes to the pathogenesis and progression of several inflammatory diseases. Moreover, high circulating levels of PMN–platelet aggregates have been reported in patients with clinical atherosclerosis, and recent studies suggest that these aggregates may play a role in vascular response to injury. It has been suggested that this heterotypic interaction between platelets and leukocytes might represent a link between hemostasis/thrombosis and the inflammatory response.

Anzeige

1.

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.PubMedCrossRef

2.

Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA. 1995;92(18):8264–8.PubMedCrossRef

3.

Peiser L, Mukhopadhyay S, Gordon S. Scavenger receptors in innate immunity. Curr Opin Immunol. 2002;14(1):123–8.PubMedCrossRef

4.

Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197–216.PubMedCrossRef

5.

Libby P, Nahrendorf M, Pittet MJ, Swirski FK. Diversity of denizens of the atherosclerotic plaque: not all monocytes are created equal. Circulation. 2008;117(25):3168–70.PubMedCrossRef

6.

Liuzzo G, Goronzy JJ, Yang H, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation. 2000;101(25):2883–8.PubMedCrossRef

7.

De Palma R, Del Galdo F, Abbate G, et al. Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: evidence for a local, intracoronary immunologic mechanism. Circulation. 2006;113:640–6.PubMedCrossRef

8.

Liuzzo G, Kopecky SL, Frye RL, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation. 1999;100(21):2135–9.PubMedCrossRef

9.

Zal B, Kaski JC, Arno G, et al. Heat-shock protein 60-reactive CD4+CD28null T cells in patients with acute coronary syndromes. Circulation. 2004;109(10):1230–5.PubMedCrossRef

10.

Nakajima T, Schulte S, Warrington KJ, et al. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation. 2002;105(5):570–5.PubMedCrossRef

11.

Pryshchep S, Sato K, Goronzy JJ, Weyand CM. T cell recognition and killing of vascular smooth muscle cells in acute coronary syndrome. Circ Res. 2006;98(9):1168–76.PubMedCrossRef

12.

Han SF, Liu P, Zhang W, et al. The opposite-direction modulation of CD4+CD25+ Tregs and T helper 1 cells in acute coronary syndromes. Clin Immunol. 2007;124(1):90–7.PubMedCrossRef

13.

Cheng X, Yu X, Ding YJ, et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol. 2008;127(1):89–97.PubMedCrossRef

14.

Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol. 2008;8:802–15.PubMedCrossRef

15.

Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol. 2004;15:1983–92.PubMedCrossRef

16.

Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 2000;191:189–94.PubMedCrossRef

17.

Soehnlein O, Weber C, Lindbom L. Neutrophil granule proteins tune monocytic cell function. Trends Immunol. 2009;30:538–46.PubMedCrossRef

18.

Borregaard N, Sorensen OE, Theilgaard-Monch K. Neutrophil granules: a library of innate immunity proteins. Trends Immunol. 2007;28:340–5.PubMedCrossRef

19.

Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ Res. 2012;110(6):875–88.PubMedCrossRef

20.

Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11(8):519–31.PubMedCrossRef

21.

Soehnlein O, Lindbom L, Weber C. Mechanisms underlying neutrophil-mediated monocyte recruitment. Blood. 2009;114(21):4613–23.PubMedCrossRef

22.

Borgeat P, Hamberg M, Samuelsson B. Transformation of arachidonic acid and homo-gamma-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxygenases. J Biol Chem. 1976;251:7816–20.PubMed

23.

Di Gennaro A, Kenne E, Wan M, Soehnlein O, Lindbom L, Haeggström JZ. Leukotriene B4-induced changes in vascular permeability are mediated by neutrophil release of heparin-binding protein (HBP/CAP37/azurocidin). FASEB J. 2009;23:1750–7.PubMedCrossRef

24.

Taekema-Roelvink ME, Kooten C, Kooij SV, Heemskerk E, Daha MR. Proteinase 3 enhances endothelial monocyte chemoattractant protein-1 production and induces increased adhesion of neutrophils to endothelial cells by upregulating intercellular cell adhesion molecule-1. J Am Soc Nephrol. 2001;12(5):932–40.PubMed

25.

Soehnlein O, Xie X, Ulbrich H, et al. Neutrophil-derived heparin-binding protein (HBP/CAP37) deposited on endothelium enhances monocyte arrest under flow conditions. J Immunol. 2005;174(10):6399–405.PubMed

26.

Chertov O, Ueda H, Xu LL, et al. Identification of human neutrophil-derived cathepsin G and azurocidin/CAP37 as chemoattractants for mononuclear cells and neutrophils. J Exp Med. 1997;186(5):739–47.PubMedCrossRef

27.

Kai-Larsen Y, Agerberth B. The role of the multifunctional peptide LL-37 in host defense. Front Biosci. 2008;13:3760–7.PubMedCrossRef

28.

Soehnlein O, Weber C. Myeloid cells in atherosclerosis: initiators and decision shapers. Semin Immunopathol. 2009;31(1):35–47.PubMedCrossRef

29.

Mocatta TJ, Pilbrow AP, Cameron VA, et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol. 2007;49:1993–2000.PubMedCrossRef

30.

Tavakoli S, Asmis R. Reactive oxygen species and thiol redox signaling in the macrophage biology of atherosclerosis. Antioxid Redox Signal. 2012;17(12):1785–95.PubMedCrossRef

31.

Woloszynek JC, Hu Y, Pham CT. Cathepsin G-regulated release of formyl peptide receptor agonists modulate neutrophil effector functions. J Biol Chem. 2012;287(41):34101–9.PubMedCrossRef

32.

Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol. 2000;68(1):9–14.PubMed

33.

Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007;449(7162):564–9.PubMedCrossRef

34.

Ganguly D, Chamilos G, Lande R, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med. 2009;206(9):1983–94.PubMedCrossRef

35.

Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515–81.PubMedCrossRef

36.

DiStasi MR, Ley K. Opening the flood-gates: how neutrophil-endothelial interactions regulate permeability. Trends Immunol. 2009;30:547–56.PubMedCrossRef

37.

Raines EW, Ferri N. Thematic review series: the immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res. 2005;46:1081–92.PubMedCrossRef

38.

Eltzschig HK, Eckle T, Mager A, et al. ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. Circ Res. 2006;99(10):1100–8.PubMedCrossRef

39.

Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002;296:2391–4.PubMedCrossRef

40.

Gündüz D, Aslam M, Krieger U, et al. Opposing effects of ATP and adenosine on barrier function of rat coronary microvasculature. J Mol Cell Cardiol. 2012;52(5):962–70.PubMedCrossRef

41.

Drechsler M, Döring Y, Megens RT, Soehnlein O. Neutrophilic granulocytes—promiscuous accelerators of atherosclerosis. Thromb Haemost. 2011;106(5):839–48.PubMedCrossRef

42.

Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol. 2008;3:279–312.PubMedCrossRef

43.

Bengtsson E, To F, Hakansson K, et al. Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:2151–6.PubMedCrossRef

44.

Cullen P, Baetta R, Bellosta S, et al. Rupture of the atherosclerotic plaque: does a good animal model exist? Arterioscler Thromb Vasc Biol. 2003;23:535–42.PubMedCrossRef

45.

Soehnlein O, Wantha S, Simsekyilmaz S, et al. Neutrophil-derived cathelicidin protects from neointimal hyperplasia. Sci Transl Med. 2011;3(103):103ra98.

46.

Yvan-Charvet L, Welch C, Pagler TA, et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via Toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation. 2008;118(18):1837–47.PubMedCrossRef

47.

Sasaki T, Kuzuya M, Nakamura K, et al. A simple method of plaque rupture induction in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:1304–9.PubMedCrossRef

48.

Van Leeuwen M, Gijbels MJ, Duijvestijn A, et al. Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR-/-mice. Arterioscler Thromb Vasc Biol. 2008;28:84–9.PubMedCrossRef

49.

Zernecke A, Bot I, Djalali-Talab Y, et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res. 2008;102:209–17.PubMedCrossRef

50.

Drechsler M, Megens R, van Zandvoort M, Weber C, Soehnlein O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation. 2010;122:1837–45.PubMedCrossRef

51.

Rotzius P, Thams S, Soehnlein O, et al. Distinct infiltration of neutrophils in lesion shoulders in ApoE-/- mice. Am J Pathol. 2010;177(1):493–500.PubMedCrossRef

52.

Döring Y, Manthey HD, Drechsler M, et al. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation. 2012;125:1673–83.PubMedCrossRef

53.

Soehnlein O, Zernecke A, Eriksson EE, et al. Neutrophil secretion products pave the way for inflammatory monocytes. Blood. 2008;112(4):1461–71.PubMedCrossRef

54.

Freidman GD, Klatsky AL, Siegelaub AB. The leukocyte count as a predictor of myocardial infarction. N Engl J Med. 1974;290:1275–8.CrossRef

55.

Furman MI, Becker RC, Yarzebski J, Savegeau J, Gore JM, Goldberg RJ. Effect of elevated leukocyte count on in-hospital mortality following acute myocardial infarction. Am J Cardiol. 1996;78:945–8.PubMedCrossRef

56.

Gillum RF, Mussolino ME, Madans JH. Counts of neutrophils, lymphocytes, and monocytes, cause-specific mortality and coronary heart disease: the NHANES-I epidemiologic follow-up study. Ann Epidemiol. 2005;15:266–71.PubMedCrossRef

57.

Nijm J, Wikby A, Tompa A, Olsson AG, Jonasson L. Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease. Am J Cardiol. 2005;95:452–6.PubMedCrossRef

58.

Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, Quiles J, Zouridakis E, Kaski JC. Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina. Atherosclerosis. 2004;175:151–7.PubMedCrossRef

59.

Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, et al. Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. Heart. 2004;90:847–52.PubMedCrossRef

60.

Mehta J, Dinerman J, Mehta P, et al. Neutrophil function in ischemic heart disease. Circulation. 1989;79:549–56.PubMedCrossRef

61.

Buffon A, Biasucci LM, Liuzzo G, D’Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002;347:5–12.PubMedCrossRef

62.

Biasucci LM, D’Onofrio G, Liuzzo G, et al. Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J Am Coll Cardiol. 1996;27:611–6.PubMedCrossRef

63.

Mazzone A, De Servi S, Ricevuti G, et al. Increased expression of neutrophils and monocyte adhesion molecules in unstable coronary artery disease. Circulation. 1993;88:358–63.PubMedCrossRef

64.

Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002;106:2894–900.PubMedCrossRef

65.

Ionita MG, van den Borne P, Catanzariti LM, et al. High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol. 2010;30(9):1842–8.PubMedCrossRef

66.

Ferrante G, Nakano M, Prati F, et al. High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes. Circulation. 2010;122:2505–13.PubMedCrossRef

67.

Lau D, Baldus S. Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharm Therap. 2006;111:16–26.CrossRef

68.

Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2005;25:1102–11.PubMedCrossRef

69.

Kumar V, Sharma A. Neutrophils: Cinderella of innate immune system. Int Immunopharmacol. 2010;10(11):1325–34.PubMedCrossRef

70.

Malle E, Marsche G, Panzenboeck U, Sattler W. Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins. Arch Biochem Biophys. 2006;445:245–55.PubMedCrossRef

71.

Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest. 1994;94:437–44.PubMedCrossRef

72.

Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999;103:1547–60.PubMedCrossRef

73.

Mohiuddin I, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Nitrotyrosine and chlorotirosine: clinical significance and biological functions in the vascular system. J Surg Res. 2006;133(143):149.

74.

Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004; 114: 529–541.

75.

Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem. 2000;275:37524–32.PubMedCrossRef

76.

Yang J, Ji R, Cheng Y, Sun JZ, Jennings LK, Zhang C. l-Arginine chlorination results in the formation of a nonselective nitric-oxide synthase inhibitor. J Pharmacol Exp Ther. 2006;318:1044–9.PubMedCrossRef

77.

Xu J, Xie Z, Reece R, Pimental D, Zou MH. Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase-derived superoxide and peroxynitrite. Arterioscler Thromb Vasc Biol. 2006;26:2688–95.PubMedCrossRef

78.

Baldus S, Rudolph V, Roiss M, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel immobilized myeloperoxidase. Circulation. 2006;113:1871–8.PubMedCrossRef

79.

Hazen SL. Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol. 2004;24(1143–6):26.

80.

Koeffler HP, Ranyard J, Pertcheck M. Myeloperoxidase: its structure and expression during myeloid differentiation. Blood. 1985;65:484–91.PubMed

81.

Owen CA, Campbell MA, Boukedes SS, Stockley RA, Campbell EJ. A discrete subpopulation of human monocytes expresses a neutrophil-like proinflammatory (P) phenotype. Am J Physiol. 1994;267(6 Pt 1):L775–85.PubMed

82.

Zhang R, Shen Z, Nauseef WM, Hazen SL. Defects in leukocyte-mediated initiation of lipid peroxidation in plasma as studied in myeloperoxidase-deficient subjects: systematic identification of multiple endogenous diffusible substrates for myeloperoxidase in plasma. Blood. 2002;99(5):1802–10.PubMed

83.

Penn MS, Patel CV, Cui MZ, DiCorleto PE, Chisolm GM. LDL increases inactive tissue factor on vascular smooth muscle cell surfaces: hydrogen peroxide activates latent cell surface tissue factor. Circulation. 1999;99(13):1753–9.PubMedCrossRef

84.

Lesnik P, Dentan C, Vonica A, Moreau M, Chapman MJ. Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell- and copper-mediated oxidation. Arterioscler Thromb Vasc Biol. 1995;15(8):1121–30.PubMedCrossRef

85.

Rees MD, Pattison DI, Davies MJ. Oxidation of heparan sulphate by hypochlorite: role of N-chloro derivatives and dichloramine-dependent fragmentation. Biochem J. 2005;391(Pt 1):125–34.PubMed

86.

Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7): a mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem. 2001;276:41279–87.PubMedCrossRef

87.

Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001;158:879–91.PubMedCrossRef

88.

Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997;99(9):2075–81.PubMedCrossRef

89.

Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol. 2004;24:1309–14.PubMedCrossRef

90.

Zhang R, Brennan ML, Fu X, et al. Association between MPO levels and risk of coronary artery disease. JAMA. 2001;286:2136–42.PubMedCrossRef

91.

Meuwese MC, Stroes ESG, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals. The EPIC-Norfolk prospective population study. JACC. 2007;50:159–65.PubMedCrossRef

92.

Li S-H, Xing Y-W, Li Z–Z, Bai SG, Wang J. Clinical implications of relationship between myeloperoxidase and acute coronary syndromes [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 2007;35:241–4.PubMed

93.

Luo HR, Loison F. Constitutive neutrophil apoptosis: mechanisms and regulation. Am J Hematol. 2008;83:288–95.PubMedCrossRef

94.

Simon HU. Neutrophil apoptosis pathways and their modifications in inflammation. Immunol Rev. 2003;193:101–10.PubMedCrossRef

95.

Cartwright GE, Athens JW, Wintrobe MM. The kinetics of granulopoiesis in normal man. Blood. 1964;24:780–803.PubMed

96.

Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005; 120:649–61.

97.

Daigle I, Simon HU. Critical role for caspases 3 and 8 in neutrophil but not in eosinophil apoptosis. Int Arch Allergy Immunol. 2001;126:147–56.PubMedCrossRef

98.

Gardai SJ, Hildeman DA, Frankel SK, et al. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. J Biol Chem. 2004;279:21085–95.PubMedCrossRef

99.

Renshaw SA, Timmons SJ, Eaton V, et al. Inflammatory neutrophils retain susceptibility to apoptosis mediated via the Fas death receptor. J Leukoc Biol. 2000;67:662–8.PubMed

100.

Kamohara H, Matsuyama W, Shimozato O, et al. Regulation of tumor necrosis factor related apoptosis inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils. Immunology. 2004;111:186–94.PubMedCrossRef

101.

Daigle I, Yousefi S, Colonna M, Green DR, Simon HU. Death receptors and SHP-1 and block cytokine-induced antiapoptotic signalling in neutrophils. Nat Med. 2002;8:61–7.PubMedCrossRef

102.

Sakamoto E, Hato F, Kato T, et al. Type I and II interferon delay human neutrophil apoptosis via activation of STAT3 and upregulation of cellular inhibitor of apoptosis 2. J Leukoc Biol. 2005;78:301–9.PubMedCrossRef

103.

Kobayashi SD, Voylch JM, Whithney AR, DeLeo FR. Spontaneous neutrophil apoptosis and regulation of cell survival by GM-CSF. J Leukoc Biol. 2005;78:1408–18.PubMedCrossRef

104.

Andonegui G, Trevani AS, Lopez DH, Raiden S, Giordano M, Geffner JR. Inhibition of human neutrophil apoptosis by platelets. J Immunol. 1997;158:3372–7.PubMed

105.

Peng SL. Neutrophil apoptosis in autoimmunity. J Mol Med. 1996;84:122–5.CrossRef

106.

Megens RT, Vijayan S, Lievens D, Döring Y, van Zandvoort M, Grommes J, Weber C, Soehnlein O. Presence of luminal neutrophil extracellular traps in atherosclerosis. Thromb Haemost. 2012;107(3):597–8.

107.

Zhao M, Song B, Pu J, et al. Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN. Nature. 2006;442:457–60.PubMedCrossRef

108.

Cross A, Barnes T, Bucknall RC, Edwards SW, Moots RJ. Neutrophil apoptosis in rheumatoid arthritis is regulated by local oxygen tensions within joints. J Leukoc Biol. 2006;80:521–6.PubMedCrossRef

109.

Bailey SM, Murnane JP. Telomeres, chromosome instability and cancer. Nucleic Acids Res. 2006;34:2408–17.PubMedCrossRef

110.

Yang J, Chang E, Cherry AM, et al. Human endothelial cell life extension by telomerase expression. J Biol Chem. 1999;274:26141–8.PubMedCrossRef

111.

Hiyama K, Hirai Y, Kyoizumi S, et al. Activation of telomerase in human lymphocytes and haematopoietic cells. J Immunol. 1995;155:3711–5.PubMed

112.

Narducci ML, Grasselli A, Biasucci LM, et al. High telomerase activity in neutrophils from unstable coronary plaques. J Am Coll Cardiol. 2007;50:2369–74.PubMedCrossRef

113.

Biffl WL, Moore EE, Moore FA, Barnett CC Jr, Carl VS, Peterson VN. IL-6 delays neutrophil apoptosis. Arch Surg. 1996;131:24–30.PubMedCrossRef

114.

Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood. 1992;80:2012–20.PubMed

115.

Robertson JD, Gale RE, Wynn RF, et al. Dynamic of telomere shortening in neutrophils and T lymphocytes during ageing and the relationship to skewed X chromosome inactivation patterns. Br J Haematol. 2000;109:272–9.PubMedCrossRef

116.

Norrback KF, Enblad G, Erlanson M, Sundström C, Roos G. Telomerase activity in Hodgkin’s disease. Blood. 1998;92:566–73.

117.

Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–5.PubMedCrossRef

118.

Wong JM, Collins K. Telomere maintenance and disease. Lancet. 2003;362:983–8.PubMedCrossRef

119.

Biasucci LM, Liuzzo G, Giubilato S, et al. Delayed neutrophil apoptosis in patients with unstable angina: relation to C-reactive protein and recurrence of instability. Eur Heart J. 2009;30:2220–5.PubMedCrossRef

120.

Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: a multistep paradigm. Cell. 1994;76:301–14.PubMedCrossRef

121.

Marcus AJ. Thrombosis and inflammation as multicellular processes: significance of cell–cell interactions. Semin Hematol. 1994;31:261–9.PubMed

122.

Larsen E, Celi A, Gilbert GE, et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell. 1989;59:305–12.PubMedCrossRef

123.

Hamburger SA, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood. 1990;75:550–4.PubMed

124.

Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood. 1996;88:146–57.PubMed

125.

Evangelista V, Manarini S, Rontondo S, et al. Platelet/polymorphonuclear leukocyte interaction in dynamic conditions: evidence of adhesion cascade and cross talk between P-selectin and the b2 integrin CD11b/CD18. Blood. 1996;88:4183–94.PubMed

126.

Wang Y, Sakuma M, Chen Z, et al. Leukocyte engagement of platelet glycoprotein Ibalpha via the integrin Mac-1 is critical for the biological response to vascular injury. Circulation. 2005;112:2993–3000.

127.

Ott I, Neumann F, Gawaz M, Schmitt M, Schömig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation. 1996;94:1239–46.PubMedCrossRef

128.

Weyrich AS, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-a secretion. J Clin Invest. 1995;95:2297–303.PubMedCrossRef

129.

Weyrich AS, Elstad MR, McEver RP, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest. 1996;97:1525–34.PubMedCrossRef

130.

Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA. 2010;107:15880–5.PubMedCrossRef

131.

Merhi Y, Provost P, Chauvet P, Théorêt JF, Phillips ML, Latour JG. Selectin blockade reduces neutrophil interaction with platelets at the site of deep arterial injury by angioplasty in pigs. Arterioscler Thromb Vasc Biol. 1999;19:372–7.PubMedCrossRef

132.

Von Brühl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209(4):819–35.CrossRef

133.

Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001;104(13):1533–7.PubMedCrossRef

134.

Garlichs CD, Eskafi S, Cicha I, et al. Delay of neutrophil apoptosis in acute coronary syndromes. J Leukoc Biol. 2004;75:828–35.PubMedCrossRef

135.

Lefer AM, Campbell B, Scalia R, Lefer DJ. Synergism between platelets and neutrophils in provoking cardiac dysfunction after ischemia and reperfusion: role of selectins. Circulation. 1998;98:1322–8.PubMedCrossRef

136.

Maugeri N, Rovere-Querini P, Evangelista V, et al. An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromes. PLoS ONE. 2012;7(6):e39484.PubMedCrossRef

137.

Maugeri N, Rovere-Querini P, Evangelista V, et al. Neutrophils phagocytose activated platelets in vivo: a phosphatidylserine, P-selectin, and ß2 integrin-dependent cell clearance program. Blood. 2009;113:5254–65.PubMedCrossRef

138.

Maugeri N, Malato S, Femia EA, et al. Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia. Blood. 2011;118:3359–66.PubMedCrossRef

Titel: Polymorphonuclear neutrophils and instability of the atherosclerotic plaque: a causative role?
verfasst von: Roberta Della Bona
Maria Teresa Cardillo
Milena Leo
Gina Biasillo
Massimo Gustapane
Francesco Trotta
Luigi M. Biasucci
Publikationsdatum: 01.06.2013
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Inflammation Research / Ausgabe 6/2013
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-013-0617-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Anzeige

Neu im Fachgebiet Innere Medizin

16.04.2024 | Spondylitis ankylosans | Nachrichten

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

16.04.2024 | Chronische Herzinsuffizienz | Nachrichten

Sind Betablocker auch für ältere herzschwache Personen nützlich?

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Manche Gestagene können das Risiko für Meningeome erhöhen

weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen